Analgesics and Anti-inflammatory Drugs Practice Questions

Q: The prostaglandin inhibiting action of Aspirin is useful in the treatment of all of the following conditions except?

Uricosuria. The therapeutic effects of Aspirin are primarily mediated by the irreversible inhibition of **Cyclooxygenase (COX-1 and COX-2)** enzymes, which prevents the synthesis of **Prostaglandins (PGs)** and **Thromboxane A2 (TXA2)** [1]. **Why Uricosuria is the Correct Answer:** Aspirin has a **dose-dependent effect** on uric acid excretion that is independent of prostaglandin inhibition. At low to moderate doses (the doses typically used for analgesia), aspirin actually **inhibits the tubular secretion of uric acid**, leading to hyperuricemia (retention of uric acid). While very high doses (>5g/day) can be uricosuric, aspirin is never used for this purpose because such doses are toxic. Therefore, its prostaglandin-inhibiting action is not the mechanism for uricosuria. **Analysis of Incorrect Options:** * **Analgesia and Antipyresis:** Aspirin reduces PGE2 levels in the hypothalamus (resetting the thermoregulatory center) and at peripheral nerve endings, effectively treating pain and fever [1]. * **Closure of Ductus Arteriosus:** Patent Ductus Arteriosus (PDA) is maintained by PGE2. Inhibiting PG synthesis promotes the closure of the ductus in neonates [2]. * **Anti-inflammatory and Antiplatelet:** Inflammation is driven by PGs, and platelet aggregation is driven by TXA2 [1]. Aspirin inhibits both, making it vital for inflammatory conditions and prophylaxis against myocardial infarction [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Low dose (75-150mg):** Antiplatelet (inhibits TXA2). * **Intermediate dose (0.3-5g):** Analgesic and Antipyretic. * **High dose (>5g):** Uricosuric (but causes Salicylism). * **Contraindication:** Aspirin is contraindicated in children with viral infections to prevent **Reye’s Syndrome**.

Q: Which of the following is a new IL-1 antagonist used in rheumatoid arthritis?

Anakinra. **Explanation:** **Anakinra** is the correct answer because it is a recombinant, non-glycosylated form of the human **Interleukin-1 receptor antagonist (IL-1Ra)**. In Rheumatoid Arthritis (RA), IL-1 is a key pro-inflammatory cytokine that mediates cartilage destruction and bone resorption. Anakinra competitively inhibits the binding of IL-1α and IL-1β to the IL-1 type I receptor, thereby reducing the inflammatory response. **Analysis of Incorrect Options:** * **Rituximab (Option B):** This is a chimeric monoclonal antibody against **CD20**, a protein found primarily on the surface of B-cells. It is used in RA cases refractory to TNF inhibitors. * **Teriparatide (Option C):** This is a recombinant form of **Parathyroid Hormone (PTH)**. It is an anabolic agent used for Osteoporosis, not an anti-inflammatory for RA. * **Adalimumab (Option D):** This is a fully human monoclonal antibody directed against **TNF-α** (Tumor Necrosis Factor-alpha), not IL-1 [1]. **High-Yield NEET-PG Pearls:** * **Other IL-1 Inhibitors:** Apart from Anakinra, newer agents include **Canakinumab** (monoclonal antibody against IL-1β) and **Rilonacept** (IL-1 trap). * **Clinical Use:** Anakinra is less commonly used than TNF inhibitors due to its shorter half-life (requires daily subcutaneous injections) and lower efficacy in RA. * **Contraindication:** Never combine IL-1 antagonists with TNF inhibitors (like Adalimumab or Etanercept) due to a significantly increased risk of serious infections [2]. * **Side Effect:** Injection site reactions are the most common adverse effect. DMARDs include a diverse group of small molecule non-biologicals and biological agents used to retard the progression of arthritic tissue destruction [3].

Q: FK 506 is a type of:

Macrolide antibiotic. **Explanation:** **FK 506**, also known as **Tacrolimus**, is a potent immunosuppressant. Chemically, it is classified as a **macrolide antibiotic** (Option C) because it contains a large macrocyclic lactone ring in its structure. However, unlike erythromycin, it lacks significant antibacterial activity and is used primarily for its immunosuppressive properties. **Mechanism of Action:** Tacrolimus binds to an intracellular protein called **FK-binding protein (FKBP-12)**. This complex inhibits **calcineurin**, a phosphatase enzyme. Inhibition of calcineurin prevents the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT), thereby blocking the transcription of **Interleukin-2 (IL-2)** and other cytokines. This results in the inhibition of T-lymphocyte activation. **Analysis of Incorrect Options:** * **Option A:** It is a small molecule drug derived from the fungus *Streptomyces tsukubaensis*, not a protein-based immunoglobulin. * **Option B:** Non-depolarizing muscle relaxants (e.g., Vecuronium, Atracurium) act on nicotinic receptors at the neuromuscular junction; Tacrolimus has no such action. * **Option D:** Opioid anesthetics (e.g., Fentanyl) act on mu-opioid receptors for analgesia; Tacrolimus does not possess analgesic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Prophylaxis of organ transplant rejection (especially liver and kidney) and topically for atopic dermatitis. * **Potency:** Tacrolimus is **10–100 times more potent** than Cyclosporine. * **Side Effects:** Nephrotoxicity (most common), neurotoxicity (tremors, seizures), and **post-transplant diabetes mellitus (PTDM)**. Unlike Cyclosporine, it does *not* typically cause hirsutism or gum hyperplasia. * **Drug Interactions:** Metabolized by **CYP3A4**; levels increase with grapefruit juice or macrolide antibiotics (like Erythromycin).

Q: Which immunosuppressant acts by inhibiting mTOR and is non-nephrotoxic?

Sirolimus. **Explanation:** **Sirolimus** (also known as **Rapamycin**) is the correct answer. It belongs to the class of drugs known as **mTOR inhibitors** (mammalian Target of Rapamycin). 1. **Mechanism of Action:** Sirolimus binds to the intracellular protein **FKBP-12**. This complex then inhibits the mTOR kinase, which is a key regulator of the cell cycle. By inhibiting mTOR, it prevents the progression of T-cells from the G1 to the S phase, thereby suppressing lymphocyte proliferation. 2. **Clinical Advantage:** Unlike Calcineurin inhibitors (CNIs), Sirolimus is notably **non-nephrotoxic**. This makes it an excellent alternative or adjunct in renal transplant patients to reduce the dose of nephrotoxic drugs. **Analysis of Incorrect Options:** * **Azathioprine:** An antimetabolite that acts as a prodrug for 6-mercaptopurine. It inhibits purine synthesis but does not involve the mTOR pathway. * **Tacrolimus:** A Calcineurin inhibitor (CNI). Like Sirolimus, it binds to FKBP-12, but the complex inhibits calcineurin, not mTOR. Crucially, Tacrolimus is **highly nephrotoxic**. * **Rapamycin:** While Rapamycin is the same chemical compound as Sirolimus, in the context of standardized exams like NEET-PG, if both names are provided, "Sirolimus" is the preferred pharmacological nomenclature. (Note: In most clinical scenarios, they are synonymous, but the question structure often tests the specific drug class name). **High-Yield NEET-PG Pearls:** * **Side Effects of Sirolimus:** While it spares the kidneys, it causes **Hyperlipidemia** (most common), thrombocytopenia, and impaired wound healing. * **Drug Interaction:** Both Tacrolimus and Sirolimus are metabolized by **CYP3A4**; grapefruit juice can increase their toxicity. * **Everolimus:** A newer mTOR inhibitor with a shorter half-life than Sirolimus.

Question 1

What is the mechanism by which opioids cause constipation in palliative care patients?

Accepted Answer

Activation of mu receptors in myenteric plexus reducing peristalsis

Answer

Inhibition of bile secretion

Answer

Direct toxic effect on intestinal mucosa

Answer

Dehydration due to increased renal sodium excretion

Question 2

The prostaglandin inhibiting action of Aspirin is useful in the treatment of all of the following conditions except?

Accepted Answer

Uricosuria

Answer

Analgesia and antipyresis

Answer

Closure of ductus arteriosus

Answer

Anti-inflammatory and antiplatelet aggregation

Question 3

Which of the following is a new IL-1 antagonist used in rheumatoid arthritis?

Accepted Answer

Anakinra

Answer

Rituximab

Answer

Teriparatide

Answer

Adalimumab

Question 4

FK 506 is a type of:

Accepted Answer

Macrolide antibiotic

Answer

Immunoglobulin antibody

Answer

Non-depolarizing muscle relaxant

Answer

Opioid anaesthetic

Question 5

Which immunosuppressant acts by inhibiting mTOR and is non-nephrotoxic?

Accepted Answer

Sirolimus

Answer

Azathioprine

Answer

Tacrolimus

Answer

Rapamycin

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?